Alternate AChE-R variants facilitate cellular metabolic activity and resistance to genotoxic stress through enolase and RACK1 interactions

Chemico-Biological Interactions

Volumn 175, Issue 1-3, 2008, Pages 11-21

  Mor, Inbal ^a   Bruck, Tal ^a   Greenberg, David ^a   Berson, Amit ^a   Schreiber, Leticia ^b   Grisaru, Dan ^b   Soreq, Hermona ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Acetylcholinesterase; ATP; Enolase; Glycolysis; p73; RACK1

Indexed keywords

ACETYLCHOLINESTERASE; ACETYLCHOLINESTERASE R; ADENOSINE TRIPHOSPHATE; ALPHA ENOLASE; CISPLATIN; ENZYME VARIANT; MUTANT PROTEIN; N ACETYLCHOLINESTERASE R; PROTEIN P73; RECEPTOR FOR ACTIVATED C KINASE 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CARCINOGENIC ACTIVITY; CELL CULTURE; CELL METABOLISM; CELL TRANSFORMATION; CHO CELL; CULTURE MEDIUM; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; GENOTOXICITY; HUMAN; HUMAN TISSUE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; STRESS; TESTIS TUMOR; TWO HYBRID SYSTEM; UPREGULATION;

ACETYLCHOLINESTERASE; AMINO ACID SEQUENCE; ANIMALS; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; CRICETULUS; DNA-BINDING PROTEINS; GTP-BINDING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR SEQUENCE DATA; MUTAGENS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; OXIDATIVE STRESS; PHOSPHOPYRUVATE HYDRATASE; PROMOTER REGIONS, GENETIC; RECEPTORS, CELL SURFACE; TESTIS; TUMOR SUPPRESSOR PROTEINS;

EID: 50649085694     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2008.05.019     Document Type: Article

References (49)

1. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 1 (2000) 57-70
2. Shaw R.J. Glucose metabolism and cancer. Curr. Opin. Cell Biol. 18 6 (2006) 598-608
3. Vidal C.J. Expression of cholinesterases in brain and non-brain tumours. Chem. Biol. Interact. 157-158 (2005) 227-232
4. Motamed-Khorasani A., Jurisica I., Letarte M., Shaw P.A., Parkes R.K., Zhang X., Evangelou A., Rosen B., Murphy K.J., and Brown T.J. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression. Oncogene 26 2 (2007) 198-214
5. Karpel R., Ben Aziz-Aloya R., Sternfeld M., Ehrlich G., Ginzberg D., Tarroni P., Clementi F., Zakut H., and Soreq H. Expression of three alternative acetylcholinesterase messenger RNAs in human tumor cell lines of different tissue origins. Exp. Cell Res. 210 2 (1994) 268-277
6. Gilboa-Geffen A., Lacoste P.P., Soreq L., Cizeron-Clairac G., Le Panse R., Truffault F., Shaked I., Soreq H., and Berrifh-Aknin S. The thymic theme of acetylcholinesterase splice variants in myasthenia gravis. Blood 109 10 (2007) 4383-4391
7. Perry C., Sklan E.H., and Soreq H. CREB regulates AChE-R-induced proliferation of human glioblastoma cells. Neoplasia 6 3 (2004) 279-286
8. Perry C., Pick M., Podoly E., Gilboa-Geffen A., Zimmerman G., Sklan E.H., Ben-Shaul Y., Diamant S., and Soreq H. Acetylcholinesterase/C terminal binding protein interactions modify Ikaros functions, causing T lymphopenia. Leukemia (2007)
9. Meshorer E., Toiber D., Zurel D., Sahly I., Dori A., Cagnano E., Schrieber L., Grisaru D., Tronke F., and Soreq H. Combinatorial complexity of 5′ alternative acetylcholinesterase transcripts and protein products. J. Biol. Chem. 279 28 (2004) 29740-29751
10. Dvir H., Harel M., Bon S., Liu W.Q., Vidal M., Garbay C., Sussman J.L., Massoulie J., and Silman I. The synaptic acetylcholinesterase tetramer assembles around a polyproline II helix. EMBO J. 23 22 (2004) 4394-4405
11. Birikh K.R., Sklan E.H., Shoham S., and Soreq H. Interaction of "readthrough" acetylcholinesterase with RACK1 and PKC{beta}II correlates with intensified fear-induced conflict behavior. Proc. Natl. Acad. Sci. U.S.A. 100 1 (2003) 283-288
12. Paraoanu L.E., and Layer P.G. Mouse acetylcholinesterase interacts in yeast with the extracellular matrix component laminin-1beta. FEBS Lett. 576 1-2 (2004) 161-164
13. Johnson G., and Moore S.W. Identification of a structural site on acetylcholinesterase that promotes neurite outgrowth and binds laminin-1 and collagen IV. Biochem. Biophys. Res. Commun. 319 2 (2004) 448-455
14. Mor I., Podoly E., Sklan E.H., Pick M., Kirschner M., Yogev L., Ber-Sheshet Itach S., Schreiber L., Geyer B., Mor T., Grisaru D., and Soreq H. Acetylcholinesterase-R increases germ cell apoptosis but enhances sperm motility. J. Cell. Mol. Med. 12 2 (2008) 479-495
15. Farchi N., Ofek K., Podoly E., Dong H., Xiang Y.Y., Diamant S., Livnah O., Li J., Hockner B., Lu W.Y., and Soreq H. Peripheral site acetylcholinesterase blockade induces RACK1-associated neuronal remodeling. Neurodegen. Dis. 4 2-3 (2007) 171-184
16. Pick M., Perry C., Lapidot T., Guimaraes-Sternberg C., Naparstek E., Deutsch V., and Soreq H. Stress-induced cholinergic signaling promotes inflammation-associated thrombopoiesis. Blood 107 8 (2006) 3397-3406
17. Mizukami Y., Iwamatsu A., Aki T., Kimura M., Nakamura K., Nao T., Okusa T., Matsuzaki M., Yoshida K., and Kobayashi S. ERK1/2 regulates intracellular ATP levels through alpha-enolase expression in cardiomyocytes exposed to ischemic hypoxia and reoxygenation. J. Biol. Chem. 279 48 (2004) 50120-50131
18. Aaronson R.M., Graven K.K., Tucci M., McDonald R.J., and Farber H.W. Non-neuronal enolase is an endothelial hypoxic stress protein. J. Biol. Chem. 270 46 (1995) 27752-27757
19. Dang C.V., and Semenza G.L. Oncogenic alterations of metabolism. Trends Biochem. Sci. 24 2 (1999) 68-72
20. Mamidipudi V., Zhang J., Lee K.C., and Cartwright C.A. RACK1 regulates G1/S progression by suppressing Src kinase activity. Mol. Cell. Biol. 24 15 (2004) 6788-6798
21. Ozaki T., Watanabe K., Nakagawa T., Miyazaki K., Takahashi M., and Nakagawara A. Function of p73, not of p53, is inhibited by the physical interaction with RACK1 and its inhibitory effect is counteracted by pRB. Oncogene 22 21 (2003) 3231-3242
22. Moll U.M., and Slade N. p63 and p73: roles in development and tumor formation. Mol. Cancer Res. 2 7 (2004) 371-386
23. Coates P.J. Regulating p73 isoforms in human tumours. J. Pathol. 210 4 (2006) 385-389
24. Concin N., Hofstetter G., Berger A., Gehmacher A., Reimer D., Watrowski R., Tong D., Schuster E., Hefler L., Heim K., Mueller-Holzner E., Marth C., Moll U.M., Zeimet A.G., and Zeillinger R. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. Clin. Cancer Res. 11 23 (2005) 8372-8383
25. Sternfeld M., Shoham S., Klein O., Flores-Flores C., Evron T., Idelson G.H., Kitsberg D., Patrick J.W., and Soreq H. Excess "readthrough" acetylcholinesterase attenuates but the "synaptic" variant intensifies neurodeterioration correlates. Proc. Natl. Acad. Sci. U.S.A. 97 16 (2000) 8647-8652
26. Grisaru D., Deutsch V., Shapira M., Pick M., Sternfeld M., Melamed-Book N., Kaufer D., Galyam N., Gait M.J., Owen D., Lessing J.B., Eldor A., and Soreq H. ARP, a peptide derived from the stress-associated acetylcholinesterase variant, has hematopoietic growth promoting activities. Mol. Med. 7 2 (2001) 93-105
27. Ellman G.L., Courtney D., Andres V.J., and Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7 (1961) 88-95
28. Almstrup K., Ottesen A.M., Sonne S.B., Hoei-Hansen C.E., Leffers H., Rajpert-De Meyts E., and Shakkebaek N.E. Genomic and gene expression signature of the pre-invasive testicular carcinoma in situ. Cell Tissue Res. 322 1 (2005) 159-165
29. Ross M., Romrell L.J., and Kaye G. Male Reproductive System, Histology: A Text and Atlas (1995), Lippincott, Williams, & Wilkins
30. Merkulova T., Lucas M., Jabet C., Lamande N., Rouzeau J.D., Gros F., Lazar M., and Keller A. Biochemical characterization of the mouse muscle-specific enolase: developmental changes in electrophoretic variants and selective binding to other proteins. Biochem. J. 323 (Pt 3) (1997) 791-800
31. Wang D., and Lippard S.J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 4 4 (2005) 307-320
32. Seidman S., Aziz Aloya R.B., Timberg R., Loewenstein Y., Velan B., Shafferman A., Liao J., Norgaard Pedersen B., Brodbeck U., and Soreq H. Overexpressed monomeric human acetylcholinesterase induces subtle ultrastructural modifications in developing neuromuscular junctions of Xenopus laevis embryos. J. Neurochem. 62 5 (1994) 1670-1681
33. McCahill A., Warwicker J., Bolger G.B., Houslay M.D., and Yarwood S.J. The RACK1 scaffold protein: a dynamic cog in cell response mechanisms. Mol. Pharmacol. 62 6 (2002) 1261-1273
34. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22 47 (2003) 7265-7279
35. Sklan E.H., Podoly E., and Soreq H. RACK1 has the nerve to act: structure meets function in the nervous system. Prog. Neurobiol. 78 2 (2006) 117-134
36. Nakagawa T., Takahashi M., Ozaki T., Watanabe K., Hayashi S., Hosoda M., Todo S., and Nakagawara A. Negative autoregulation of p73 and p53 by DeltaNp73 in regulating differentiation and survival of human neuroblastoma cells. Cancer Lett. 197 1-2 (2003) 105-109
37. Chan W.M., Siu W.Y., Lau A., and Poon R.Y. How many mutant p53 molecules are needed to inactivate a tetramer?. Mol. Cell. Biol. 24 8 (2004) 3536-3551
38. Horwich A., Shipley J., and Huddart R. Testicular germ-cell cancer. Lancet 367 9512 (2006) 754-765
39. Pelicano H., Martin D.S., Xu R.H., and Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 25 34 (2006) 4633-4646
40. Altenberg B., and Greulich K.O. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 84 6 (2004) 1014-1020
41. Majumder P.K., Febbo P.G., Bikoff R., Berger R., Xue Q., McMahon L.M., Manola J., Brugarolas J., MacDonnell T.J., Golub T.R., Loda M., Lane H.A., and Sellers W.R. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 10 6 (2004) 594-601
42. Ramanathan A., Wang C., and Schreiber S.L. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc. Natl. Acad. Sci. U.S.A. 102 17 (2005) 5992-5997
43. Tompa P. The interplay between structure and function in intrinsically unstructured proteins. FEBS Lett. 579 15 (2005) 3346-3354
44. Casciano I., Mazzocco K., Boni L., Pagnan G., Banelli B., Allemanni G., Ponzoni M., Tonini G.P., and Romani M. Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ. 9 3 (2002) 246-251
45. Zhang X.J., Yang L., Zhao Q., Caen J.P., He H.Y., Jin Q.H., Guo L.H., Alemany M., Zhang L.Y., and Shi Y.F. Induction of acetylcholinesterase expression during apoptosis in various cell types. Cell Death Differ. 9 8 (2002) 790-800
46. Park S.E., Kim N.D., and Yoo Y.H. Acetylcholinesterase plays a pivotal role in apoptosome formation. Cancer Res. 64 8 (2004) 2652-2655
47. Kehat R., Zemel E., Cuenca N., Evron T., Toiber D., Loewenstein A., Soreq H., and Perlman I. A novel isoform of acetylcholinesterase exacerbates photoreceptors death after photic stress. Invest Ophthalmol. Vis. Sci. 48 3 (2007) 1290-1297
48. Deutsch V.R., Pick M., Perry C., Grisaru D., Hemo Y., Golan-Hadari D., Grant A., Eldor A., and Sopreq H. The stress-associated acetylcholinesterase variant AChE-R is expressed in human CD34 (+) hematopoietic progenitors and its C-terminal peptide ARP promotes their proliferation. Exp. Hematol. 30 10 (2002) 1153-1161
49. Saifudeen Z., Diavolitsis V., Stefkova J., Dipp S., Fan H., and El-Dahr S.S. Spatiotemporal switch from DeltaNp73 to TAp73 isoforms during nephrogenesis: impact on differentiation gene expression. J. Biol. Chem. 280 24 (2005) 23094-23102